Plain-English translation of NCT06504940 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called orelabrutinib combined with chemotherapy drugs for people who have never been treated for marginal zone lymphoma, a type of blood cancer. After the initial combination treatment, if you respond well, you would continue taking the medication alone for maintenance therapy. The goal is to find a treatment plan that works well and has manageable side effects.
Doctors don't yet have a clear best treatment for newly diagnosed marginal zone lymphoma. This medication has shown promise in patients who've had previous treatment, so researchers want to test whether giving it earlier—combined with chemotherapy—could help more patients achieve good results.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll be placed into one of two groups based on your age and overall fitness. You'll receive either 3 or 6 cycles of the medication combined with chemotherapy drugs (depending on your group), with each cycle lasting 28 days. If your cancer responds well to this treatment, you'll continue with the medication alone for up to 18–21 more cycles. Throughout the trial, you'll have regular blood tests and monitoring visits to check how you're responding and watch for side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China